368 related articles for article (PubMed ID: 34456921)
1. Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.
Alves E; McLeish E; Blancafort P; Coudert JD; Gaudieri S
Front Immunol; 2021; 12():712722. PubMed ID: 34456921
[TBL] [Abstract][Full Text] [Related]
2. The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition.
Chaouat AE; Seliger B; Mandelboim O; Schmiedel D
Front Immunol; 2021; 12():714799. PubMed ID: 34721381
[TBL] [Abstract][Full Text] [Related]
3. Innate immune recognition of double-stranded RNA triggers increased expression of NKG2D ligands after virus infection.
Esteso G; Guerra S; Valés-Gómez M; Reyburn HT
J Biol Chem; 2017 Dec; 292(50):20472-20480. PubMed ID: 28986447
[TBL] [Abstract][Full Text] [Related]
4. Viral inhibitors of NKG2D ligands for tumor surveillance.
Chávez-Blanco A; Chacón-Salinas R; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
Expert Opin Ther Targets; 2016 Nov; 20(11):1375-1387. PubMed ID: 27322108
[TBL] [Abstract][Full Text] [Related]
5. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
6. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
[TBL] [Abstract][Full Text] [Related]
7. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
[TBL] [Abstract][Full Text] [Related]
8. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
9. The Paradoxical Role of NKG2D in Cancer Immunity.
Sheppard S; Ferry A; Guedes J; Guerra N
Front Immunol; 2018; 9():1808. PubMed ID: 30150983
[TBL] [Abstract][Full Text] [Related]
10. NKG2D Receptor and Its Ligands in Host Defense.
Lanier LL
Cancer Immunol Res; 2015 Jun; 3(6):575-82. PubMed ID: 26041808
[TBL] [Abstract][Full Text] [Related]
11. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
12. Porcine UL-16 Binding Protein 1 Is Not a Functional Ligand for the Human Natural Killer Cell Activating Receptor NKG2D.
Lopez KJ; Spence JP; Li W; Zhang W; Wei B; Cross-Najafi AA; Butler JR; Cooper DKC; Ekser B; Li P
Cells; 2023 Nov; 12(22):. PubMed ID: 37998322
[TBL] [Abstract][Full Text] [Related]
13. NKG2D and its ligands in cancer.
Dhar P; Wu JD
Curr Opin Immunol; 2018 Apr; 51():55-61. PubMed ID: 29525346
[TBL] [Abstract][Full Text] [Related]
14. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
15. A disease-linked
Zuo J; Willcox CR; Mohammed F; Davey M; Hunter S; Khan K; Antoun A; Katakia P; Croudace J; Inman C; Parry H; Briggs D; Malladi R; Willcox BE; Moss P
Sci Signal; 2017 May; 10(481):. PubMed ID: 28559451
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas based targeting of host and viral genes as an antiviral strategy.
Koujah L; Shukla D; Naqvi AR
Semin Cell Dev Biol; 2019 Dec; 96():53-64. PubMed ID: 30953741
[TBL] [Abstract][Full Text] [Related]
17. NKG2D and Its Ligands: "One for All, All for One".
Zingoni A; Molfetta R; Fionda C; Soriani A; Paolini R; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():476. PubMed ID: 29662484
[TBL] [Abstract][Full Text] [Related]
18. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
19. Immune evasion by proteolytic shedding of natural killer group 2, member D ligands in
Anthofer M; Windisch M; Haller R; Ehmann S; Wrighton S; Miller M; Schernthanner L; Kufferath I; Schauer S; Jelušić B; Kienesberger S; Zechner EL; Posselt G; Vales-Gomez M; Reyburn HT; Gorkiewicz G
Front Immunol; 2024; 15():1282680. PubMed ID: 38318189
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
